var data={"title":"Flumazenil: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Flumazenil: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6207?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=flumazenil-patient-drug-information\" class=\"drug drug_patient\">see &quot;Flumazenil: Patient drug information&quot;</a> and <a href=\"topic.htm?path=flumazenil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Flumazenil: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708776\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Seizures:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of flumazenil has been associated with the occurrence of seizures. These are most frequent in patients who have been on benzodiazepines for long-term sedation or in overdose cases where patients are showing signs of serious cyclic antidepressant overdose. Practitioners should individualize the dosage of flumazenil and be prepared to manage seizures.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172028\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Anexate;</li>\n      <li>Flumazenil Injection;</li>\n      <li>Flumazenil Injection, USP;</li>\n      <li>Romazicon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172071\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidote</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172031\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Benzodiazepine reversal when used in conscious sedation or general anesthesia:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial dose: 0.2 mg over 15 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Repeat doses (maximum: 4 doses): If the desired level of consciousness is not obtained, 0.2 mg may be repeated at 1-minute intervals.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maximum total cumulative dose: 1 mg (usual total dose: 0.6 to 1 mg). In the event of resedation: Repeat doses may be given at 20-minute intervals as needed at 0.2 mg per minute to a maximum of 1 mg total dose and 3 mg in 1 hour.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Management of benzodiazepine overdose:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Initial dose: 0.2 mg over 30 seconds; if the desired level of consciousness is not obtained 30 seconds after the dose, 0.3 mg can be given over 30 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Repeat doses: 0.5 mg over 30 seconds repeated at 1-minute intervals</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Maximum total cumulative dose: 3 mg (usual total dose: 1 to 3 mg).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patients with a partial response at 3 mg may require (rare) additional titration up to a total dose of 5 mg (although doses &gt;3 mg do not reliably produce additional effects). If a patient has not responded 5 minutes after a cumulative dose of 5 mg, the major cause of sedation is not likely due to benzodiazepines or may be due to exposure to additional CNS depressants (eg, opioids). In the event of resedation, repeat doses may be given at 20-minute intervals if needed, at 0.5 mg per minute to a maximum of 1 mg total dose and 3 mg in 1 hour.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172050\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=flumazenil-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Flumazenil: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Reversal of benzodiazepine when used in conscious sedation:</b> Children &ge;1 year and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Initial dose: 0.01 mg/kg (maximum dose: 0.2 mg) given over 15 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repeat doses (maximum: 4 doses): If the desired level of consciousness is not obtained, 0.01 mg/kg (maximum dose: 0.2 mg) repeated at 1-minute intervals</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum total cumulative dose: 1 mg or 0.05 mg/kg (whichever is lower)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mean total dose: 0.65 mg (range: 0.08 to 1 mg)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172032\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. No differences in safety or efficacy have been reported; however, increased sensitivity may occur in some elderly patients.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172033\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment provided in manufacturer's labeling; however, pharmacokinetics are not significantly affected by renal failure (CrCl &lt;10 mL/minute) or hemodialysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172034\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">Initial reversal: No dosage adjustment necessary. Repeat doses: Reduce dose or frequency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172006\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.5 mg/5 mL (5 mL); 1 mg/10 mL (10 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171991\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172009\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Administer in freely-running IV into large vein.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Management of benzodiazepine overdose: </b>Administer over 30 seconds.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of benzodiazepine when used in conscious sedation:</b> Administer over 15 seconds.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172007\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Benzodiazepine reversal when used in conscious sedation or general anesthesia:</b> Complete or partial reversal of the sedative effects of benzodiazepines used in conscious sedation and general anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Management of benzodiazepine overdose:</b> Treatment of benzodiazepine overdose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7914344\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Flumazenil may be confused with influenza virus vaccine</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171998\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Gastrointestinal: Vomiting (11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Palpitation (3% to 9%), flushing (1% to 3%), thrombophlebitis (1% to 3%), vasodilatation (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Ataxia (10%), dizziness (10%), vertigo (10%), agitation (3% to 9%), anxiety (3% to 9%), insomnia (3% to 9%), nervousness (3% to 9%), depersonalization (1% to 3%), depression (1% to 3%), dysphoria (1% to 3%), emotional lability (1% to 3%; including crying), euphoria (1% to 3%), fatigue (1% to 3%), headache (1% to 3%), hypoesthesia (1% to 3%), malaise (1% to 3%), paranoia (1% to 3%), paresthesia (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Dermatological disease (skin abnormality: 1% to 3%), diaphoresis (1% to 3%), skin rash (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hot flash (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Xerostomia (3% to 9%), nausea (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Pain at injection site (3% to 9%), injection site reaction (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (1% to 3%), tremor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (3% to 9%), lacrimation (1% to 3%), visual disturbance (1% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea (3% to 9%), hyperventilation (3% to 9%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Atrial tachycardia (paroxysmal), auditory disturbance, bradycardia, cardiac arrhythmia, chest pain, confusion, decreased blood pressure, delirium, drowsiness, fear, hiccups, hyperacusis, hypertension, increased blood pressure, lack of concentration, panic attack, reversible hearing loss, rigors, seizure (including generalized), sensation of cold, shivering, stupor, tachycardia, tinnitus, tongue edema, ventricular tachycardia, voice disorder, withdrawal syndrome</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172012\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to flumazenil, benzodiazepines, or any component of the formulation; patients given benzodiazepines for control of potentially life-threatening conditions (eg, control of intracranial pressure or status epilepticus); patients who may have ingested or are showing signs of cyclic-antidepressant overdosage.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171995\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Amnesia: Does not consistently reverse amnesia; patient may not recall verbal instructions after procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving) for 24 hours after discharge.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Resedation: Occurs more frequently in patients where a large single dose or cumulative dose of a benzodiazepine has been administered along with a neuromuscular-blocking agent and multiple anesthetic agents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Respiratory depression: Should not rely upon to reverse respiratory depression/hypoventilation. Flumazenil is not a substitute for evaluation of oxygenation. Establishing an airway and assisting ventilation, as necessary, is always the initial step in overdose management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: <b>[US Boxed Warning]: Benzodiazepine reversal may result in seizures; seizures may occur more frequently in patients on benzodiazepines for long-term sedation or following tricyclic antidepressant overdose. Dose should be individualized and practitioners should be prepared to manage seizures.</b> Seizures may also develop in patients with concurrent major sedative-hypnotic drug withdrawal, recent therapy with repeated doses of parenteral benzodiazepines, myoclonic jerking or seizure activity prior to flumazenil administration. Use with caution in patients relying on a benzodiazepine for seizure control.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Head injury: Use with caution in patients with a head injury; may alter cerebral blood flow or precipitate convulsions in patients receiving benzodiazepines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic dysfunction; repeated doses of the drug should be reduced in frequency or amount.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Panic disorder: Use with caution in patients with a history of panic disorder; may provoke panic attacks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug/alcohol dependence: Use caution in drug and ethanol-dependent patients; these patients may also be dependent on benzodiazepines.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intensive care patients: Should be used with caution in the intensive care unit because of increased risk of unrecognized benzodiazepine dependence in such settings.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Should not be used to diagnose benzodiazepine-induced sedation. Reverse neuromuscular blockade before considering use. Flumazenil does not antagonize the CNS effects of other GABA agonists (such as ethanol, barbiturates, or general anesthetics); nor does it reverse opioids. Not recommended for treatment of benzodiazepine dependence.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Overdose use: Use with caution in patients with mixed drug overdoses; toxic effects of other drugs taken may emerge once benzodiazepine effects are reversed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299345\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172000\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8456&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Hypnotics (Nonbenzodiazepine): Flumazenil may diminish the sedative effect of Hypnotics (Nonbenzodiazepine). <b> Exceptions: </b>Ramelteon; Suvorexant; Tasimelteon.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172002\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172014\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Teratogenic effects were not seen in animal reproduction studies. Embryocidal effects were seen at large doses. Use during labor and delivery is not recommended. In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962080\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if flumazenil is excreted in breast milk. The manufacturer recommends that caution be used if administering to breast-feeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15962118\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Avoid alcohol for the first 24 hours after administration or as long as the effects of benzodiazepines exist.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172004\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor for return of sedation, respiratory depression, benzodiazepine withdrawal, and other residual effects of benzodiazepines for at least 2 hours and until the patient is stable and resedation is unlikely.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F171994\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Competitively inhibits the activity at the benzodiazepine receptor site on the GABA/benzodiazepine receptor complex. Flumazenil does not antagonize the CNS effect of drugs affecting GABA-ergic neurons by means other than the benzodiazepine receptor (ethanol, barbiturates, general anesthetics) and does not reverse the effects of opioids</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172011\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">\n      <b>Note:</b> Follows a two compartment open model; Clearance and V<sub>d</sub> per kg are similar for children and adults, but children display more variability </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: 1-2 minutes; 80% response within 3 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peak effect: 6-10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Resedation occurs after ~1 hour (range: 19-50 minutes); duration related to dose given and benzodiazepine plasma concentrations; reversal effects of flumazenil may wear off before effects of benzodiazepine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Initial V<sub>d</sub>: 0.5 L/kg; V<sub>dss</sub>: 0.9-1.1 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~50% (~67% of which is bound to albumin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; dependent upon hepatic blood flow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children: Terminal: 20-75 minutes (mean: 40 minutes)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: Alpha: 4-11 minutes; Terminal: 40-80 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Moderate hepatic dysfunction: 1.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Severe hepatic impairment: 2.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces; urine (&lt;1% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Dependent upon hepatic blood flow; Adults: 0.8-1 L/hour/kg </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323156\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Flumazenil Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/5 mL (5 mL): $7.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/10 mL (10 mL): $148.31</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172015\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anexate (AE, AT, AU, BE, BF, BG, BH, BJ, CH, CI, CN, CY, CZ, DE, EE, EG, ES, ET, FR, GH, GM, GN, GR, HK, HR, HU, ID, IE, IL, IQ, IR, IT, JO, JP, KE, KR, KW, LB, LK, LR, LU, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, PK, PL, PT, QA, RO, SA, SC, SD, SI, SK, SL, SN, SY, TN, TR, TW, TZ, UG, VN, YE, ZA, ZM, ZW);</li>\n      <li>Antabenz (MY);</li>\n      <li>Antadona (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Anzenil (PH);</li>\n      <li>Fadaflumaz (AR);</li>\n      <li>Flumage (AR);</li>\n      <li>Flumazen (AU);</li>\n      <li>Flumil (PY, UY);</li>\n      <li>Flunexate (JO, LB);</li>\n      <li>Flunexil (BR);</li>\n      <li>Flunil (KR);</li>\n      <li>Fluoxem (CL);</li>\n      <li>Lai Yi (CN);</li>\n      <li>Lanexat (BB, BM, BR, BS, BZ, CL, CO, CR, DK, DO, EC, FI, GT, GY, HN, JM, MX, NI, PA, PE, PY, SE, SR, SV, TT, UY, VE);</li>\n      <li>Outnestin (CR, DO, GT, HN, NI, PA, SV)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    An H, Godwin J. Flumazenil in benzodiazepine overdose. <i>CMAJ</i>. 2016;188(17-18):E537.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/27920113/pubmed\" target=\"_blank\" id=\"27920113\">27920113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B, &quot;Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2003, 67(2):133-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baktai G, Szekely E, Marialigeti T, et al, &ldquo;Use of Midazolam (Dormicum) and Flumazenil (Anexate) in Paediatric Bronchology,&rdquo; <i>Curr Med Res Opin</i>, 1992, 12(9):552-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/1582237/pubmed\" target=\"_blank\" id=\"1582237\">1582237</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brammer G, Gilby R, Walter FG, et al, &ldquo;Continuous Intravenous Flumazenil Infusion for Benzodiazepine Poisoning,&rdquo; <i>Vet Hum Toxicol</i>, 2000, 42(5):280-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/11003118/pubmed\" target=\"_blank\" id=\"11003118\">11003118</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chern CH, Chern TL, Hu SC, et al, &ldquo;Complete and Partial Response to Flumazenil in Patients With Suspected Benzodiazepine Overdose,&rdquo; <i>Am J Emerg Med</i>, 1995, 13(3):372-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/7755838/pubmed\" target=\"_blank\" id=\"7755838\">7755838</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chern CH, Chern TL, Wang LM, et al, &ldquo;Continuous Flumazenil Infusion in Preventing Complications Arising From Severe Benzodiazepine Intoxication,&rdquo; <i>Am J Emerg Med</i>, 1998, 16(3):238-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/9596422/pubmed\" target=\"_blank\" id=\"9596422\">9596422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Clark RF, Sage TA, Tunget C, et al, &ldquo;Delayed Onset Lorazepam Poisoning Successfully Reversed By Flumazenil in a Child: Case Report and Review of the Literature,&rdquo; <i>Pediatr Emerg Care</i>, 1995, 11(1):32-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/7739960/pubmed\" target=\"_blank\" id=\"7739960\">7739960</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flumazenil (prescribing information). Rockford, IL: Mylan; November 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ghouri AF, Ramirez Ruiz MA, and White PF, &ldquo;Effect of Flumazenil on Recovery After Midazolam and Propofol Sedation,&rdquo; <i>Anesthesiology</i>, 1994, 81(2):330-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haverkos GP, Di Salvo RP, and Imhoff TE, &ldquo;Fatal Seizures After Flumazenil Administration in a Patient With Mixed Overdose,&rdquo; <i>Ann Pharmacother</i>, 1994, 28(12):1347-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/7696723/pubmed\" target=\"_blank\" id=\"7696723\">7696723</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hojer J, Baehrendtz S, Magnusson A, et al, &ldquo;A Placebo-Controlled Trial of Flumazenil Given by Continuous Infusion in Severe Benzodiazepine Overdosage,&rdquo; <i>Acta Anaesthesiol Scand</i>, 1991, 35(7):584-90.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/1686131/pubmed\" target=\"_blank\" id=\"1686131\">1686131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hood SD, Norman A, Hince DA, Melichar JK, Hulse GK. Benzodiazepine dependence and its treatment with low dose flumazenil. <i>Br J Clin Pharmacol</i>. 2014;77(2):285-294.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/23126253/pubmed\" target=\"_blank\" id=\"23126253\">23126253</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jones RD, Lawson AD, Andrew LJ, et al, &ldquo;Antagonism of the Hypnotic Effect of Midazolam in Children: A Randomized, Double Blind Study of Placebo and Flumazenil Administered After Midazolam-Induced Anaesthesia,&rdquo; <i>Br J Anaesth</i>, 1991, 66(6):660-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/2064881/pubmed\" target=\"_blank\" id=\"2064881\">2064881</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Massanari M, Novitsky J, and Reinstein LJ, &ldquo;Paradoxical Reactions in Children Associated With Midazolam Use During Endoscopy,&rdquo; <i>Clin Pediatr (Phila)</i>, 1997, 36(12):681-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mathieu-Nolf M, Bab&eacute; MA, Coquelle-Couplet V, et al, &ldquo;Flumazenil Use in an Emergency Department: A Survey,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2001, 39(1):15-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/11327221/pubmed\" target=\"_blank\" id=\"11327221\">11327221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McDuffee AT and Tobias JD, &ldquo;Seizure After Flumazenil Administration in a Pediatric Patient,&rdquo; <i>Pediatr Emerg Care</i>, 1995, 11(3):186-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/7651879/pubmed\" target=\"_blank\" id=\"7651879\">7651879</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moore PW, Donovan JW, Burkhart KK, et al. Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated deliriumtoxicity during treatment of alcohol withdrawal, a retrospective review at one center. <i>J Med Toxicol</i>. 2014;10(2):126-132.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/24619543/pubmed\" target=\"_blank\" id=\"24619543\">24619543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nguyen TT, Troendle M, Cumpston K, Rose SR, Wills BK. Lack of adverse effects from flumazenil administration: an ED observational study. <i>Am J Emerg Med</i>. 2015;33(11):1677-1679.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/26324010/pubmed\" target=\"_blank\" id=\"26324010\">26324010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reisner-Keller LA and Pham Z, &ldquo;Oral Flumazenil in the Treatment of Epilepsy,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(5):530-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/7655138/pubmed\" target=\"_blank\" id=\"7655138\">7655138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richard P, Autret E, Bardol J, et al, &ldquo;The Use of Flumazenil in a Neonate,&rdquo; <i>J Toxicol Clin Toxicol</i>, 1991, 29(1):137-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/2005661/pubmed\" target=\"_blank\" id=\"2005661\">2005661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roald OK and Dahl V, &ldquo;Flunitrazepam Intoxication in a Child Successfully Treated With the Benzodiazepine Antagonist Flumazenil,&rdquo; <i>Crit Care Med</i>, 1989, 17(12):1355-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/2512053/pubmed\" target=\"_blank\" id=\"2512053\">2512053</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shannon M, Albers G, Burkhart K, et al, &ldquo;Safety and Efficacy of Flumazenil in the Reversal of Benzodiazepine-Induced Conscious Sedation. The Flumazenil Pediatric Study Group,&rdquo; <i>J Pediatr</i>, 1997, 131(4):582-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/9386663/pubmed\" target=\"_blank\" id=\"9386663\">9386663</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spivey WH, &ldquo;Flumazenil and Seizures: Analysis of 43 Cases,&rdquo; <i>Clin Ther</i>, 1992, 14(2):292-305.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/1611650/pubmed\" target=\"_blank\" id=\"1611650\">1611650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sugarman JM and Paul RI, &ldquo;Flumazenil: A Review,&rdquo; <i>Pediatr Emerg Care</i>, 1994, 10(1):37-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/8177806/pubmed\" target=\"_blank\" id=\"8177806\">8177806</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trujillo MH, Guerrero J, Fragachan C, et al, &ldquo;Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration,&rdquo; <i>Crit Care Med</i>, 1998, 26(2):377-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/flumazenil-drug-information/abstract-text/9468179/pubmed\" target=\"_blank\" id=\"9468179\">9468179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiley J and Wiley C, &ldquo;Benzodiazepine Ingestions in Children,&rdquo; <i>Clin Toxicol</i>, 1995, 33(5):520.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8456 Version 139.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708776\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F172028\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F172071\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F172031\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F172050\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F172032\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F172033\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F172034\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F172006\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F171991\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F172009\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F172007\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F7914344\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F171998\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F172012\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F171995\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299345\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F172000\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F172002\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F172014\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F15962080\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F15962118\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F172004\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F171994\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F172011\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323156\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F172015\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8456|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=flumazenil-patient-drug-information\" class=\"drug drug_patient\">Flumazenil: Patient drug information</a></li><li><a href=\"topic.htm?path=flumazenil-pediatric-drug-information\" class=\"drug drug_pediatric\">Flumazenil: Pediatric drug information</a></li></ul></div></div>","javascript":null}